Alkermes (ALKS)
(Delayed Data from NSDQ)
$23.75 USD
-0.27 (-1.12%)
Updated May 28, 2024 04:00 PM ET
After-Market: $23.73 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Alkermes plc [ALKS]
Reports for Purchase
Showing records 81 - 100 ( 287 total )
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Keytruda Supply Deal with Merck Provides Benefits, But We Still Await Strategic Partnership; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
The Evolution of the Alkermes Pipeline; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Alkermes Powers Through Environment with Solid 4Q20, While 2021 Encourages Promise; Reiterate Neutral and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Strategic Action Plan Announced as Alkermes Looks to Jump-Start Shares; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
ALKS-3831 Issued a CRL on Manufacturing Concern, Though Speedy Resolution Expected; Reiterate Neutral and Keep PT at $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Promising ALKS 4230 Data Update Presented at SITC; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Alkermes Beats 3Q Earning, Though We Think COVID-19 Overhang Remains; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
ALKS-3831 Does Enough to Clear AdCom, but Does It Offer Enough to Drive Adoption? Three Key Takeaways
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Takeaways From ALKS 3831 AdCom Briefing Materials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D